Ipsen SA

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

12 Feb 2025 21:57:00 By Nasdaq GlobeNewswire

Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Feb 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen - Half year statement - 2024 12 31

07 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Dec 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

02 Dec 2024 22:00:00 By Nasdaq GlobeNewswire

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

22 Oct 2024 22:00:00 By Nasdaq GlobeNewswire

Ipsen receives its second Shingo Prize for operational excellence

14 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

23 Sep 2024 04:13:10 By Nasdaq GlobeNewswire

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

20 Sep 2024 05:57:57 By Nasdaq GlobeNewswire

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

16 Sep 2024 05:45:00 By Nasdaq GlobeNewswire

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

15 Sep 2024 05:45:00 By Nasdaq GlobeNewswire

Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

04 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

13 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

06 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

05 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

30 Jul 2024 09:00:00 By Nasdaq GlobeNewswire